Chronic Heart Failure With Reduced Ejection Fraction Clinical Trial
Official title:
A Double-Blind, Placebo-Controlled, Randomized, Multicenter, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor of Angiotensinogen Production, Administered Subcutaneously Over 12 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction
The purpose of this study is to evaluate the effect of IONIS-AGT-LRX weekly subcutaneous (SC) injection on plasma angiotensinogen (AGT) concentration from Baseline to Study Day 85 (Week 13) and to evaluate the effect of IONIS-AGT-LRx weekly SC injection on plasma AGT concentration and N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) levels at each scheduled visit in chronic heart failure participants with reduced ejection fraction (HFrEF).
This study will be a Phase 2, double-blind, randomized, placebo-controlled study in up to 72 participants. Participants will be randomized in a 2:1 ratio to either IONIS-AGT-LRX or matching placebo and receive a once-weekly SC treatment. The length of participation in the study will be approximately 35 weeks, which includes an up to 10-week screening period, a 12-week treatment period, and a 13-week post-treatment period. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02861534 -
A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)
|
Phase 3 | |
| Completed |
NCT02226120 -
Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction
|
Phase 3 | |
| Recruiting |
NCT06148935 -
An Observational Study to Learn More About the Use of Vericiguat in Korean People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in Real-world Setting
|
||
| Active, not recruiting |
NCT05093933 -
A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)
|
Phase 3 | |
| Not yet recruiting |
NCT06195930 -
A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction
|
Phase 2 | |
| Recruiting |
NCT04983043 -
Efficacy and Safety of QiShen YiQi Dripping Pills in Chronic Heart Failure
|
Phase 2 | |
| Active, not recruiting |
NCT04840914 -
A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction
|
Phase 1 | |
| Completed |
NCT02768298 -
Exercise Capacity Study of LCZ696 vs. Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction.
|
Phase 4 | |
| Active, not recruiting |
NCT05974189 -
The VERIFY Study: An Observational Study Called VERIFY to Learn More About the Use of Vericiguat in People With Chronic Heart Failure With Reduced Ejection Fraction
|
||
| Recruiting |
NCT05553886 -
S086 Tablets for Chronic Heart Failure With Reduced Ejection Fraction
|
Phase 3 | |
| Completed |
NCT02900378 -
randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure
|
Phase 3 | |
| Withdrawn |
NCT04464525 -
Omecamtiv Mecarbil Post-trial Access Study
|
Phase 3 | |
| Recruiting |
NCT05658458 -
A Study to Learn How Well the Drug Vericiguat Works and How Safe it is Under Real World Conditions in Indian Participants After Worsening of a Long-term Heart Condition in Which the Left Side of the Heart Does Not Pump Blood as Well as it Should (Chronic Heart Failure With Reduced Ejection Fraction)
|
Phase 4 | |
| Recruiting |
NCT05728502 -
An Observational Study, Called VERI-China, to Learn More About How Well Vericiguat Works and How Safe it is in Real-world Setting in People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in China
|
||
| Active, not recruiting |
NCT06363110 -
An Observational Study to Learn More About Vericiguat Treatment Patterns and Its Safety in People With Chronic Heart Failure With Reduced Ejection Fraction in Routine Medical Care in the United States
|